A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe ARDS From COVID-19.

Michael E BowdishChristina E BarkauskasJessica R OverbeyRobert L GottliebKeren OsmanAbhijit DuggalMary E MarksJonathan HupfEustace FernandesBradley G LeshnowerJonathan L GolobAlexander IribarneAthos J RassiasEllen G MoqueteKaren O'SullivanHelena L ChangJudson B WilliamsSam ParniaNirav C PatelNimesh D DesaiAndrew M VeksteinBeth A HollisterTammie PossematoChristian RomeroPeter C HouElizabeth BurkeJack HayesFred GrossmanSilviu ItescuMarc GillinovFrancis D PaganiPatrick T O'GaraMichael J MackPeter K SmithEmilia BagiellaAlan J MoskowitzAnnetine C Gelijns

Published in: American journal of respiratory and critical care medicine (2022)

gov, ID:NCT04371393. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keyphrases

coronavirus disease
sars cov
acute respiratory distress syndrome
bone marrow
minimally invasive
extracorporeal membrane oxygenation
high intensity
mechanical ventilation
early onset
structure activity relationship
neural network
drug induced